首发精神分裂症、双相情感障碍和重性抑郁症患者的不同水平的前脉冲抑制。
Different levels of prepulse inhibition among patients with first-episode schizophrenia, bipolar disorder and major depressive disorder.
机构信息
From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li).
From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
出版信息
J Psychiatry Neurosci. 2024 Jan 18;49(1):E1-E10. doi: 10.1503/jpn.230083. Print 2024 Jan-Feb.
BACKGROUND
Deficits in prepulse inhibition may be a common feature in first-episode schizophrenia, bipolar disorder (BD) and major depressive disorder (MDD). We sought to explore the levels and viability of prepulse inhibition to differentiate first-episode schizophrenia, BD and MDD in patient populations.
METHODS
We tested patients with first-episode schizophrenia, BD or MDD and healthy controls using prepulse inhibition paradigms, namely perceived spatial co-location (PSC-PPI) and perceived spatial separation (PSS-PPI).
RESULTS
We included 53 patients with first-episode schizophrenia, 30 with BD and 25 with MDD, as well as 82 healthy controls. The PSS-PPI indicated that the levels of prepulse inhibition were smallest to largest, respectively, in the first-episode schizophrenia, BD, MDD and control groups. Relative to the healthy controls, the prepulse inhibition deficits in the first-episode schizophrenia group were significant ( < 0.001), but the prepulse inhibitions were similar between patients with BD and healthy controls, and between patients with MDD and healthy controls. The receiver operating characteristic curve analysis showed that PSS-PPI (area under the curve [AUC] 0.73, < 0.001) and latency (AUC 0.72, < 0.001) were significant for differentiating patients with first-episode schizophrenia or BD from healthy controls.
LIMITATIONS
The demographics of the 4 groups were not ideally matched. We did not perform cognitive assessments. The possible confounding effect of medications on prepulse inhibition could not be eliminated.
CONCLUSION
The level of prepulse inhibition among patients with first-episode schizophrenia was the lowest, with levels among patients with BD, patients with MDD and healthy controls increasingly higher. The PSS-PPI paradigm was more effective than PSC-PPI to recognize deficits in prepulse inhibition. These results provide a basis for further research on biological indicators that can assist differential diagnoses in psychosis.
背景
在首发精神分裂症、双相情感障碍（BD）和重性抑郁障碍（MDD）中，前脉冲抑制缺陷可能是一个共同的特征。我们试图探索前脉冲抑制的水平和活力，以区分首发精神分裂症、BD 和 MDD 患者人群。
方法
我们使用前脉冲抑制范式，即感知空间共定位（PSC-PPI）和感知空间分离（PSS-PPI），对首发精神分裂症、BD 或 MDD 患者和健康对照者进行测试。
结果
我们纳入了 53 例首发精神分裂症患者、30 例 BD 患者和 25 例 MDD 患者，以及 82 名健康对照者。PSS-PPI 表明，前脉冲抑制水平从首发精神分裂症、BD、MDD 和对照组中依次最小到最大。与健康对照组相比，首发精神分裂症组的前脉冲抑制缺陷显著（<0.001），而 BD 患者和健康对照组之间以及 MDD 患者和健康对照组之间的前脉冲抑制无差异。受试者工作特征曲线分析显示，PSS-PPI（曲线下面积[AUC]0.73，<0.001）和潜伏期（AUC 0.72，<0.001）对区分首发精神分裂症或 BD 患者与健康对照组有显著意义。
局限性
4 组的人口统计学特征并不理想匹配。我们没有进行认知评估。药物对前脉冲抑制的可能混杂影响无法消除。
结论
首发精神分裂症患者的前脉冲抑制水平最低，BD 患者、MDD 患者和健康对照者的前脉冲抑制水平逐渐升高。PSS-PPI 范式比 PSC-PPI 更有效地识别前脉冲抑制缺陷。这些结果为进一步研究可辅助精神病鉴别诊断的生物学指标提供了依据。
Zotero 插件